Comparison

Liraglutide vs. Pramlintid

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Liraglutide	Pramlintid
Germany	Prescription	Unapproved
United States	Prescription	Prescription

Full entries

Frequently asked questions

What is the difference between Liraglutide and Pramlintid?: Liraglutide is classified as "Metabolic", while Pramlintid is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Liraglutide or Pramlintid?: The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Liraglutide and Pramlintid in Germany and the United States?: Germany: Liraglutide — Prescription, Pramlintid — Unapproved. United States: Liraglutide — Prescription, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Liraglutide

Pramlintid

Germany

Prescription

Unapproved

United States

Prescription

Frequently asked questions

What is the difference between Liraglutide and Pramlintid?

Liraglutide is classified as "Metabolic", while Pramlintid is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Liraglutide or Pramlintid?

The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Liraglutide and Pramlintid in Germany and the United States?

Germany: Liraglutide — Prescription, Pramlintid — Unapproved. United States: Liraglutide — Prescription, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.